Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill targets tough cancers with genetic flaw

NCT ID NCT07213609

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This study tests an experimental oral drug, GSK5460025, alone or with other cancer drugs, in adults whose solid tumors have specific genetic changes (dMMR or MSI-H). The goal is to see if the drug can shrink tumors and to check its safety. About 47 people with advanced cancers that have not responded to other treatments will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GSK5460025 (an oral drug)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat cancers that have specific genetic features.
What could go wrong
This is an early-phase trial with only 47 participants, so it is not yet known if the drug is effective or safe in larger groups. Side effects and lack of tumor shrinkage are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal cancer colorectal neoplasm endometrial cancer endometrium neoplasm mismatch repair cancer syndrome 1 neoplasm rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS NEOPLASMS, COLORECTAL

Contacts and locations

Locations

  • GSK Investigational Site

    RECRUITING

    Aurora, Colorado, 80045, United States

  • GSK Investigational Site

    RECRUITING

    Detroit, Michigan, 48201, United States

  • GSK Investigational Site

    RECRUITING

    Canton, Ohio, 44718, United States

  • GSK Investigational Site

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • GSK Investigational Site

    RECRUITING

    Hamilton, Ontario, L8V 5C2, Canada

  • GSK Investigational Site

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • GSK Investigational Site

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • GSK Investigational Site

    RECRUITING

    Copenhagen, 2100, Denmark

  • GSK Investigational Site

    RECRUITING

    Chiba, 277-8577, Japan

  • GSK Investigational Site

    RECRUITING

    Osaka, 573-1191, Japan

  • GSK Investigational Site

    RECRUITING

    Tokyo, 104-0045, Japan

  • GSK Investigational Site

    RECRUITING

    Tokyo, 135-8550, Japan

  • GSK Investigational Site

    RECRUITING

    Amsterdam, 1066 CX, Netherlands

  • GSK Investigational Site

    RECRUITING

    Utrecht, 3584 CX, Netherlands

  • GSK Investigational Site

    RECRUITING

    Barcelona, 08035, Spain

  • GSK Investigational Site

    RECRUITING

    Madrid, 28034, Spain

  • GSK Investigational Site

    RECRUITING

    Madrid, 28040, Spain

  • GSK Investigational Site

    RECRUITING

    Madrid, 28041, Spain

  • GSK Investigational Site

    RECRUITING

    Madrid, 28050, Spain

  • GSK Investigational Site

    RECRUITING

    Lund, 22185, Sweden

  • GSK Investigational Site

    RECRUITING

    Stockholm, 17164, Sweden

  • GSK Investigational Site

    RECRUITING

    Uppsala, 751 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.